Iterum Therapeutics plc (ITRMF) EBIT (2017 - 2025)

Iterum Therapeutics has reported EBIT for 9 years, with the latest figure at -$7.7 million in Q3 2025.

• On a quarterly basis, EBIT fell 58.2% year-over-year to -$7.7 million in Q3 2025; TTM through Sep 2025 was -$20.6 million, a 21.99% increase from a year earlier, with the FY2024 full-year figure at -$18.7 million, up 60.61% from the prior year.
• EBIT was -$7.7 million for Q3 2025 at Iterum Therapeutics, down from -$5.5 million in the prior quarter.
• The five-year high for EBIT was -$3.7 million in Q4 2024, with the low at -$16.7 million in Q3 2023.
• Average EBIT over 5 years is -$7.3 million, with a median of -$7.0 million recorded in 2021.
• The sharpest annual moves came in 2023 and 2024: EBIT sank 137.21% in 2023, then jumped 70.71% in 2024.
• Over 5 years, EBIT stood at -$6.8 million in 2021, then dropped by 16.06% to -$7.9 million in 2022, then plunged by 44.22% to -$11.4 million in 2023, then jumped by 67.89% to -$3.7 million in 2024, then tumbled by 110.65% to -$7.7 million in 2025.
• The last three EBIT figures came in at -$7.7 million (Q3 2025), -$5.5 million (Q2 2025), and -$3.7 million (Q1 2025), per Business Quant data.